Edoxaban tosylate monohydrateEdoxaban tosylate monohydrate
MedChemExpress (MCE)
HY-10264B
1229194-11-9
DU-176b monohydrate
99.91%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
Edoxaban monohydrate (1, 1 and 5 minutes respectively) prolongs PT, TT and APTT of human plasma in a concentration-dependent manner[1].?Edoxaban monohydrate inhibits thrombin-induced platelet aggregation, with an IC50 of 2.90 μM[1].
Edoxaban monohydrate (0.5, 2.5 and 12.5 mg/kg
p.o.
once) significantly and dose-dependently reduces the thrombus formation and prolongs PT[1].
IC50: 2.90 µM (platelet aggregation), Ki: 0.561 nM (free human FXa), 2.98 nM (prothrombinase), 0.715 nM (cynomolgus monkey FXa), 0.457 nM (rabbit FXa)[1] In Vitro Edoxaban monohydrate (1, 1 and 5 minutes respectively) prolongs PT, TT and APTT of human plasma in a concentration-dependent manner[1].?Edoxaban monohydrate inhibits thrombin-induced platelet aggregation, with an IC50 of 2.90 μM[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Edoxaban tosylate monohydrate Related Antibodies Cell Viability Assay[1] Cell Line: Human, rat, cynomolgus monkey and rabbit plasma
Human platelet
| | | |
| | | | | |
[1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep
6(9):1542-9. [Content Brief]